PAVmed Inc (OQ:PAVM)

Business Focus: Advanced Medical Equipment & Technology

Mar 26, 2024 07:32 pm ET
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
Lucid's quarterly revenue increased 33 percent sequentially
Mar 21, 2024 09:30 am ET
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% compared to upper gastrointestinal endoscopy
Mar 21, 2024 08:30 am ET
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX
The incubator, PMX, and medical device firm Hatch Medical, execute joint venture agreement to complete their development and commercialization, starting with PortIO
Feb 16, 2024 04:00 pm ET
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
NEW YORK, Feb. 16, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that it was notified by the World Trade Center Health Program ("WTCHP") that, due to a clerical error, the EsoGuard® Esophageal DNA test was incorrectly listed as a covered benefit. WTCHP advised Lucid on the further steps required, including engaging directly with its Clinical Centers of Excellence.  Lucid has a strong record o
Feb 15, 2024 06:45 am ET
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
Contrasts EsoCheck's powerful cell collection capabilities to "cruder, decades-old" technologies during comments on patient access to medical technology innovation
Feb 08, 2024 06:45 am ET
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants
Dec 12, 2023 07:30 am ET
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
Studies demonstrate real-world clinical utility of EsoGuard testing to detect esophageal precancer
Dec 11, 2023 08:00 am ET
PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders
PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock
Dec 04, 2023 03:20 pm ET
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock
Nov 16, 2023 08:00 am ET
Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts
Industry veterans join executive team as VP, Market Access and VP, Employer Markets
Nov 14, 2023 04:43 pm ET
PAVmed Provides Business Update and Third Quarter Financial Results
Lucid's quarterly revenue increased 392 percent sequentially
Nov 13, 2023 04:40 pm ET
Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
Quarterly EsoGuard® test volume and revenue increased 17 percent and 392 percent sequentially, respectively
Nov 09, 2023 08:00 am ET
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day
EsoGuard 2.0 incorporates advanced molecular techniques and leverages improvements in sample DNA yields and processes to enhance assay performance and lower costs
Nov 02, 2023 09:18 am ET
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
Lishan Aklog, M.D., Chairman & CEO, to Present November 16, 2023, in New York
Nov 01, 2023 09:10 am ET
Oct 31, 2023 09:00 am ET
Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection
Clinical registries are collecting real-world clinical utility and clinical validity data on EsoGuard testing in general at-risk populations and firefighters, respectively
Oct 31, 2023 08:55 am ET
Sep 21, 2023 08:30 am ET
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 21, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or "Lucid Diagnostics"), a commercial-stage cancer prevention diagnostics company, today announced their participation in the 2023 Cantor Fitzgerald Global Healthcare Conference in New York City.  
Sep 21, 2023 08:30 am ET
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 21, 2023 /PRNewswire/ --  PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or "Lucid Diagnostics"), a commercial-stage cancer prevention diagnostics company, today announced their participation in the 2023 Cantor Fitzgerald Global Healthcare Conference in New York City.  
Jul 31, 2023 06:19 pm ET
Jul 31, 2023 06:00 pm ET
Jul 26, 2023 08:30 am ET
Lucid Diagnostics to Present at the Canaccord Genuity 43rd Annual Growth Conference
NEW YORK, July 26, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that Shaun O'Neil, Executive Vice President & Chief Operating Officer, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 11:30 am Eastern Time at the InterContinental Boston Hotel in Boston, MA.
Jul 19, 2023 09:04 am ET
PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Cover
Advocated stronger transparency and predictability, and inclusion of diagnostics, in federal proposals to improve equitable access to innovative lifesaving technologies
Jun 28, 2023 04:05 pm ET
PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
NEW YORK, June 28, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it received a written notice (the "Extension Notice") from the Nasdaq Stock Market LLC ("Nasdaq") granting the Company a 180-day extension to regain compliance with Nasdaq's $1.00 minimum bid price requirement as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Rule"). The Company was first notified by Nasdaq on December 29, 2022, and ori
Jun 14, 2023 04:05 pm ET
PAVmed to Participate in Healthcare Virtual Conference Presented by Maxim Group LLC
Dr. Lishan Aklog, PAVmed CEO, to participate in Fireside Chat with Maxim's Anthony Vendetti on Wednesday, June 21, 2023, at 1:30 PM ET.
Jun 05, 2023 07:00 am ET
Lucid Diagnostics Launches First EsoGuard® Mobile Test Unit
First esophageal precancer detection event utilizing an EsoGuard mobile test unit to be hosted today by Florida Digestive Health Specialists in Sarasota, Florida
Jun 02, 2023 07:00 am ET
PAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding Member
NEW YORK, June 2, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced its participation as a founding member of CancerX – a public-private partnership co-hosted by Moffitt Cancer Center and the Digital Medicine Society ("DiMe"), alongside the Office for the National Coordinator for Health Information Technology ("ONC") and Office of the Assistant Secreta
May 16, 2023 05:00 pm ET
PAVmed Provides Business Update and First Quarter Financial Results
EsoGuard® test volume gains momentum as Lucid expands high-volume testing events
May 15, 2023 06:21 pm ET
Lucid Diagnostics Provides Business Update and First Quarter Financial Results
EsoGuard® test volume increases 57 percent sequentially and 245 percent year-on-year
May 11, 2023 08:45 am ET
Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference
EsoGuard® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in most prevalent and challenging precancer subgroup—short segment non-dysplastic Barrett's Esophagus
May 05, 2023 09:00 am ET
May 05, 2023 09:00 am ET
PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023
Conference Call and Webcast at 8:30AM Eastern Time
Apr 25, 2023 08:45 am ET
PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President
Manning Brings Vast Digital Health Experience Focused on Demonstrable Growth and Commercial Excellence
Apr 19, 2023 08:45 am ET
PAVmed Digital Health Subsidiary, Veris Health, to Present Comprehensive Meta-analysis on Impact of Remote Patient Monitoring in Oncology at HIMSS
Company presenting at highly influential HIMSS23 Global Health Conference, today, April 19, 2023 from 11:30 a.m. to 12:30 p.m. CDT.
Apr 17, 2023 09:45 pm ET
Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference
NEW YORK, April 17, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Dr. Lishan Aklog, Chairman and Chief Executive Officer; and Dennis McGrath, Chief Financial Officer will present at the 22nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 11:00 AM ET.
Mar 31, 2023 12:45 pm ET
Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer
Foundational LCD, to be effective May 14, 2023, incorporates key feedback to 2022 draft, including updated guidelines recommending non-endoscopic biomarker testing
Mar 14, 2023 07:09 pm ET
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results
Conference call and webcast to be held tomorrow, March 15th at 8:30 AM EST
Mar 14, 2023 01:28 pm ET
/C O R R E C T I O N -- Lucid Diagnostics/
In the news release, Lucid Diagnostics Provides Business Update and Fourth Quarter and Full Year 2022 Financial Results, issued 13-Mar-2023 by Lucid Diagnostics over PR Newswire, we are advised by the company that the information in the financial tables has been updated. The complete, corrected release follows:
Mar 13, 2023 06:21 pm ET
Lucid Diagnostics Provides Business Update and Fourth Quarter and Full Year 2022 Financial Results
4Q22 and projected 1Q23 EsoGuard® test volume increases 8 and 36 percent sequentially and 288 and 300 percent annually.
Jan 17, 2023 04:05 pm ET
PAVmed and Lucid Diagnostics Provide Strategic Business Update
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or “Lucid Diagnostics”), a commercial-stage cancer prevention diagnostics company, and Veris Health Inc. (“Veris”), a private digital health company focused on enhanced personalized cancer care, today provided a strategic business update, outlining near-term strategic priorities and resource reallocation. The companies will prioritize ne
Jan 11, 2023 08:00 am ET
PAVmed and Lucid Diagnostics to Provide Strategic Business Update
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries
Dec 22, 2022 08:25 am ET
PAVmed Partners with Novosound on Ultrasound Imaging Technology
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has entered into a license option and joint research and development agreement with Novosound Ltd. (“Novosound”), a venture-backed technology
Dec 15, 2022 08:25 am ET
PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that its majority-owned digital health subsidiary Veris Health Inc. (“Veris”), has commercially launched its Veris Cancer Care Platform™ (“Veris CCP”)
Dec 08, 2022 08:25 am ET
Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of
Dec 01, 2022 08:25 am ET
Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of
Nov 15, 2022 04:20 pm ET
PAVmed Provides Business Update and Third Quarter 2022 Financial Results
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”
Nov 14, 2022 04:40 pm ET
Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of
Nov 11, 2022 08:25 am ET
PAVmed to Participate in BTIG Digital Health Forum
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”, the “Company”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today announced that
Nov 10, 2022 08:25 am ET
Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of
Nov 09, 2022 08:25 am ET
Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of
Nov 03, 2022 08:25 am ET
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2022
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical device company today announced that the Company will host a business update conference call and webcast on Tuesday, November 15, 2022, at 4:30 PM EDT. During the call,
Nov 02, 2022 08:25 am ET
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the Company will host a business update conference call and webcast on Monday, November 14, 2022, at 4:30 PM EDT. During the call,
Aug 30, 2022 08:25 am ET
PAVmed to Participate in the Lake Street 6th Annual Best Ideas Growth Conference and the A.G.P. Virtual MedTech Conference
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical device company operating in the medical device, diagnostics, and digital health sectors, today announced that Lishan Aklog, M.D., the Company’s Chairman and CEO, will participate in one-on-one investor meetings at Lake Street Capital Markets’
Aug 16, 2022 04:40 pm ET
PAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”
Aug 15, 2022 04:25 pm ET
Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of
Aug 11, 2022 08:25 am ET
Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of
Aug 04, 2022 08:25 am ET
Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of
Aug 03, 2022 08:25 am ET
PAVmed to Hold a Business Update Conference Call on August 16, 2022
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical device company today announced that the Company will host a business update conference call on Tuesday, August 16, 2022, at 4:30 PM EDT. During the call,
Jul 19, 2022 08:25 am ET
PAVmed Chairman & CEO Lishan Aklog, M.D. Named to Savoy’s 2022 Most Influential Black Executives in Corporate America
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today announced that its Chairman & Chief Executive Officer
Jul 18, 2022 08:25 am ET
Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of
May 13, 2022 08:25 am ET
PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary
May 12, 2022 04:38 pm ET
PAVmed PAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Results
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”
May 11, 2022 04:00 pm ET
Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of
May 09, 2022 08:25 am ET
Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of
May 04, 2022 07:03 am ET
Lucid Diagnostics Selects Veeva Vault CDMS for EsoGuard® Study
Vault CDMS to manage clinical data for trial involving Barrett's esophagus and esophageal adenocarcinoma patients
Apr 28, 2022 04:05 pm ET
PAVmed Announces Procedural Update on its Settlement of a Previously Disclosed Class Action Lawsuit
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced a procedural update on its settlement of a previously disclosed class action lawsuit. As previously...
Apr 26, 2022 08:25 am ET
PAVmed to Hold a Business Update Conference Call on May 12, 2022
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the Company will host a business update conference call on Thursday, May 12, 2022, at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer, will provide a busin
Apr 25, 2022 08:25 am ET
Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the Company will host a business update conference call on Wednesday, May 11, 2022, at 4:30 PM EDT. During the call, Lishan Aklog, M.
Apr 22, 2022 09:35 am ET
Thinking about buying stock in Chindata, PAVmed, AT&T, Gentex Corp, or Oscar Health?
NEW YORK, April 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CD, PAVM, T, GNTX, and OSCR.
Mar 30, 2022 08:25 am ET
Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that
Mar 29, 2022 04:11 pm ET
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”
Mar 24, 2022 08:25 am ET
PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that investigators at the
Mar 23, 2022 08:25 am ET
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that it has launched Lucid Test Centers in three new metropolitan areas—Seattle, Washington, Portland, Oregon, and Boise, Idaho. Patients in these cities with chronic heartburn, also known as gastroesophageal reflux disease (“GERD”), and an order from their own physician or from a telemedicine physician provided to them after self-referral, can now undergo a brief, non-inva
Mar 17, 2022 08:25 am ET
PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced that physicians at the Clinica Porto Azul in Barranquilla, Colombia successfully implanted the Company’s PortIO™ Intraosseous Infusion System in three patients—the first human implants of the device—as part of its IRB-approved first-in-human (FIH) clinical study of up to 40 patients. All patients have also undergone successful infusion of fluids consistent with the study protocol and the device’s intended use. No complications have occurred.
Mar 10, 2022 08:25 am ET
PAVmed Subsidiary Veris Health Launches World-Class Technology Advisory Board
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company today announced that its majority-owned digital health subsidiary Veris Health (“Veris”) has launched a world-class technology advisory board consisting of Silicon Valley luminaries with broad expertise in software development, hardware engineering, data and analytics, machine learning, and consumer engagement. Silicon Valley pioneer Rich Page, an early Apple alumnus who co-founded NeXT Computer with Steve Jobs, will serve as chair. The advisory board held its inaugural meeting
Mar 08, 2022 08:30 am ET
PAVmed to Hold a Business Update Conference Call on March 29, 2022
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the companies will host a business update conference call on Tuesday, March 29, 2022, at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman, and Chief Executive Officer, will provide a b
Mar 07, 2022 08:30 am ET
Lucid Diagnostics to Hold a Business Update Conference Call on March 28, 2022
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the companies will host a business update conference call on Monday, March 28, 2022, at 4:30 PM EDT. During the call, Lishan Aklog, M
Mar 04, 2022 08:25 am ET
Lucid Diagnostics to Participate in the LSI USA ’22 Emerging Medtech Summit
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that
Mar 03, 2022 08:25 am ET
PAVmed Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that a new, wholly owned subsidiary of Lucid, LucidDx Labs Inc. (“LucidDx Labs”) has acquired from ResearchDx, Inc. (“RDx”), a CLIA-certified, CAP-accredited clinical laboratory operator located in Irvine, CA, certain licenses and other related assets necessary for LucidDx Labs to operate its own new CLIA-certified, CAP-accredited clinical laboratory located in Lake Forest,
Feb 24, 2022 08:25 am ET
PAVmed Appoints Shaun O’Neil as Chief Operating Officer
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), today announced the appointment of Shaun O’Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O’Neil has served as PAVmed’s Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will se
Feb 15, 2022 08:25 am ET
Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), today announced the appointment of prominent healthcare services industry leader and president of Care Solutions for Evernorth, Joan Harvey, to its Board of Directors. Ms. Harvey will serve as a member of the Company’s Audit and Compensation Committees.
Feb 10, 2022 08:25 am ET
Lucid Diagnostics to Participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dr. Lishan Aklog, Chairman and CEO, will participate in a Fireside Chat at the
Jan 12, 2022 08:25 am ET
PAVmed and Lucid Diagnostics Welcome New Full-Time Investor Relations Team
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention diagnostics company, today announced they have launched a new, full-time investor relations team to serve both companies.
Jan 06, 2022 08:30 am ET
Lucid Diagnostics to Participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Lishan Aklog, Chairman and CEO, will participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference on January 11, 2022, at 11:30 AM EST. The live presentation can be accessed on the “Investor Relations” section of Lucid Diagnostics’ website at
Dec 01, 2021 08:30 am ET
PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced it has launched its EsoGuard Telemedicine Program in partnership with UpScriptHealth, a leading, nationwide, direct-to-consumer telemedicine company.
Nov 17, 2021 08:30 am ET
Lucid Diagnostics to Present at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dennis McGrath, Chief Financial Officer, will present a corporate update at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 4:00 PM EST. For more information on the conference, visit
Nov 16, 2021 04:13 pm ET
PAVmed and Lucid Provide Business Update and Preliminary Third Quarter 2021 Financial Results
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention diagnostics company today provided a joint business update for the companies and discussed preliminary financial results for the six and nine months ended September 30, 2021.
Nov 11, 2021 08:30 am ET
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced it has launched Lucid Test Centers in three new metropolitan areas—Denver, Salt Lake City, and Las Vegas. Patients in these cities with chronic heartburn, also known as gastroesophageal reflux disease (“GERD”), who are referred by their primary care physician (PCP) or who self-refer can now undergo a rapid, non-invasive, office-based test to detect esophageal precancer befo
Nov 03, 2021 08:30 am ET
PAVmed and Lucid to Hold Joint Business Update Conference Call on November 16, 2021
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical diagnostics company today announced that the companies will host a joint business update conference call on Tuesday, November 16, 2021, at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the companies, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath,
Oct 29, 2021 08:30 am ET
Veris Health Showcased in PAVmed Digital Health Virtual Investor Event
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, hosted a virtual investor event with several hundred participants on October 26, 2021. The event, Veris Heath: Bringing Digital Health to Cancer Care, focused on PAVmed’s digital health subsidiary Veris Health (“Veris”).
Oct 28, 2021 08:30 am ET
Lucid Diagnostics’ EsoGuard Esophageal DNA Test Wins “Diagnostics Innovation of the Year” Award
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced its EsoGuard® Esophageal DNA Test has been selected as winner of the “Diagnostics Innovation of the Year” award in the inaugural awards program conducted by
Oct 25, 2021 08:30 am ET
PAVmed Digital Health Subsidiary Veris Health Appoints Sunny Webb as Chief Technology Officer
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, and its digital health subsidiary Veris Health (“Veris”) today announced the appointment of Silicon Valley technology executive Sunny Webb as Veris’ Chief Technology Officer and PAVmed’s VP, Data & Analytics.
Oct 21, 2021 12:59 pm ET
ADDING MULTIMEDIA Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the appointment of highly accomplished molecular biologist Suman M. Verma, M.D., Ph.D. as Lucid’s Chief Scientific Officer and PAVmed’s VP, Molecular Diagnostics.
Oct 21, 2021 08:30 am ET
Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the appointment of highly accomplished molecular biologist Suman M. Verma, M.D., Ph.D. as Lucid’s Chief Scientific Officer and PAVmed’s VP, Molecular Diagnostics.
Oct 18, 2021 06:09 pm ET
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the closing on October 18, 2021 of its initial public offering (the “Offering”) of 5,000,000 shares of common stock at a price to the public of $14.00 per share for total gross proceeds of $70,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.
Oct 18, 2021 05:45 pm ET
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the closing on October 18, 2021 of its initial public...
Oct 13, 2021 10:15 pm ET
Lucid Diagnostics Announces Pricing of Initial Public Offering
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the pricing of its initial public offering of...
Oct 13, 2021 09:28 pm ET
Lucid Diagnostics Announces Pricing of Initial Public Offering
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares are being offered by Lucid. The gross proceeds to Lucid from the offering, before deducting underwriting discounts, commissions and other offering expenses payable by Lucid, are expected to be $70,000,000. In addition, Lucid has granted the underwriters a 30
Oct 07, 2021 11:41 am ET
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced a wholly owned subsidiary of the Company has entered into a definitive membership...
Oct 07, 2021 09:30 am ET
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced a wholly owned subsidiary of the Company has entered into a definitive membership interests purchase agreement with Martin Von Dyck, the sole member and owner of North Carolina-based CapNostics, LLC, which manufactures EsophaCap®—a U.S. FDA 510(k)-cleared and European CE Mark certified, non-endoscopic esophageal cell collection device which has been used in pre-commercial clinical research of esophageal precancer b
Sep 30, 2021 10:34 am ET
PAVmed to Host Digital Health Virtual Investor Event
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that on October 26, 2021, from 1 to 3 PM EDT, it will host a virtual investor event focused on its digital health subsidiary Veris Health (“Veris”) entitled Veris Heath: Bringing Digital Health to Cancer Care. Attendees may register for the event
Sep 23, 2021 09:30 am ET
PAVmed Subsidiary, Lucid Diagnostics, Files Registration Statement for Proposed Initial Public Offering
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, and its majority-owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), announced yesterday that Lucid has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Lucid Diagnostics intends to list its common stock on The Nasdaq Stock Ma
Sep 23, 2021 08:30 am ET
Thinking about buying stock in Matinas BioPharma, BlackBerry, Sundial Growers, PAVmed, or Orchard Therapeutics?
NEW YORK, Sept. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MTNB, BB, SNDL, PAVM, and ORTX.
Sep 21, 2021 09:30 am ET
PAVmed Subsidiary Veris Health Joins Microsoft for Startups Global Program and Engages Loka as Software Development Partner
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Veris Health Inc. (“Veris”) has been accepted into Microsoft for Startups, a global program from Microsoft dedicated to accelerating the trajectory of startups. The Company also announced that Veris has entered into a definitive services agreement with leading full-service Silicon Valley-based full-stack software development firm Loka Inc. (“Loka”) to build its remote digital healthcare platform.
Sep 07, 2021 10:04 am ET
PAVmed to Participate in September Investor and MedTech Conferences
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the company’s management team will participate in the
Aug 12, 2021 04:14 pm ET
PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its major subsidiary, Lucid Diagnostics Inc. (“Lucid”), and discussed preliminary financial results for the three and six months ended June 30, 2021.
Aug 10, 2021 09:30 am ET
PAVmed Subsidiary Lucid Diagnostics Launches First Lucid Test Centers
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its majority owned subsidiary Lucid Diagnostics Inc. (“Lucid”) has begun testing patients referred by primary care physicians (“PCPs”) at three Lucid Test Centers in the Phoenix metropolitan area. Patients with chronic heartburn, also known as gastroesophageal reflux disease (“GERD”), who are referred to the centers undergo a rapid non-invasive office procedure, performed by Lucid-employed clinical personnel, using Lucid
Aug 05, 2021 09:30 am ET
PAVmed to Present at the 41st Annual Canaccord Genuity Growth Conference
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer will present a corporate update at the 41st Annual Canaccord Genuity Growth Conference on August 11, 2021, at 5:00 PM EDT.
Aug 03, 2021 09:30 am ET
Global Industry Executive Aster Angagaw Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that prominent global industry executive Aster Angagaw has joined the Board of Directors of its majority owned subsidiary Lucid Diagnostics Inc. (“Lucid”). Ms. Angagaw will serve on the Company’s Audit and Nominating Committees.
Aug 02, 2021 12:31 pm ET
CORRECTING and REPLACING PAVmed to Hold Business Update Conference Call on August 12, 2021
First paragraph, first sentence of release should read: ...Thursday, August 12, 2021, at 4:30 PM EDT (instead of Monday, August 12, 2021, at 4:30 PM EDT).
Aug 02, 2021 09:30 am ET
PAVmed to Hold Business Update Conference Call on August 12, 2021
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conference call on Monday, August 12, 2021, at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s President and Chief Financial Officer, will discuss second quarter 2021 financial r
Jul 28, 2021 09:30 am ET
Stanley Lapidus, Founder and Former Chairman & CEO of Exact Sciences, Joins PAVmed Subsidiary Lucid Diagnostics as Vice Chairman of its Board of Directors
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that medical diagnostics pioneer Stanley N. Lapidus, founder and former Chairman and CEO of Exact Sciences (Nasdaq: EXAS), has joined its majority owned subsidiary Lucid Diagnostics Inc. (“Lucid”) as Vice Chairman of Lucid’s Board of Directors.
Jul 22, 2021 09:30 am ET
PAVmed Subsidiary Lucid Diagnostics Launches Strategic Partnership with Direct-to-Consumer Telemedicine Company UpScriptHealth
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Lucid Diagnostics Inc. (“Lucid”) has entered into a definitive agreement with UpScriptHealth (“UpScript”), a leading, nationwide, direct-to-consumer telemedicine company. Pursuant to the agreement, UpScript will support Lucid’s upcoming EsoGuard Telemedicine Program by providing a Lucid-branded web-based telemedicine platform for patients with chronic heartburn symptoms to request video evaluation by
Jun 14, 2021 09:30 am ET
Tim Baxter, Former CEO of Samsung Electronics North America and Global Technology Industry Leader, Joins PAVmed Board of Directors
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent global technology industry leader Tim Baxter, to its...
Jun 10, 2021 09:30 am ET
PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major subsidiary, Lucid Diagnostics Inc. (“Lucid”), has completed European IVDD CE Mark...
Jun 02, 2021 09:30 am ET
PAVmed Launches Digital Health Company Veris Health Inc.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the launch of a new subsidiary, digital health company Veris Health Inc. (“Veris”),...
May 26, 2021 09:30 am ET
PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck® Esophageal Cell Collection Device
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), today announced that Lucid’s EsoCheck® Esophageal Cell...
May 25, 2021 09:30 am ET
PAVmed Receives European CE Mark Certification for its CarpX® Minimally Invasive Carpal Tunnel Device
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it has received CE Mark certification for its CarpX® minimally invasive carpal...
May 24, 2021 09:30 am ET
Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics’ EsoCheck and EsoGuard Technologies
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), today announced that David M. Poppers, M.D. Ph.D.,...
May 17, 2021 04:00 pm ET
PAVmed Provides Business Update and First Quarter 2021 Financial Results
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its major subsidiary, Lucid Diagnostics Inc....
May 13, 2021 09:30 am ET
PAVmed Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”), a highly differentiated, multi-product, commercial-stage medical technology company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), announced today that David Poppers, M.D....
May 06, 2021 09:30 am ET
PAVmed Subsidiary Lucid Diagnostics Expands Commercial Leadership Team
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Lucid Diagnostics Inc. (“Lucid” or the “Company”) has...
May 03, 2021 09:30 am ET
PAVmed to Hold Business Update Conference Call on May 17, 2021
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conference call on Monday, May 17, 2021 at...
Apr 29, 2021 09:30 am ET
Dr. Jacque Sokolov Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Lucid Diagnostics Inc. (“Lucid” or the “Company”) has appointed nationally...
Apr 27, 2021 09:30 am ET
Global Industry Executive Debbie White Joins PAVmed Board of Directors
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent UK-based global industry executive, Debbie White, to...
Apr 15, 2021 09:30 am ET
PAVmed Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare Technology CEO by Healthcare Technology Report
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a commercial-stage, multi-product medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer and Executive Chairman of its...
Apr 08, 2021 09:30 am ET
PAVmed to Present at the 20th Annual Needham Healthcare Conference
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer will present...
Mar 10, 2021 09:30 am ET
PAVmed to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer will present...
Mar 03, 2021 09:30 am ET
PAVmed Retires Convertible Debt
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it has retired all of the Company’s outstanding convertible debt, applying...
Mar 01, 2021 09:30 am ET
PAVmed Chairman and Chief Executive Officer Lishan Aklog, M.D., Elected to AdvaMed Board of Directors
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the Advanced Medical Technology Association (AdvaMed), the world’s leading...
Feb 25, 2021 12:37 pm ET
PAVmed Announces Closing of its Public Offering of Common Stock
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced underwritten public offering (the “Offering”) of...
Feb 23, 2021 09:00 am ET
PAVmed Announces Pricing of $45 Million Public Offering of Common Stock
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of...
Feb 22, 2021 04:13 pm ET
PAVmed Announces Proposed Public Offering of Common Stock
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it is commencing an underwritten public offering of its common stock (the...
Feb 22, 2021 08:18 am ET
PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (“Lucid”)...
Feb 18, 2021 09:30 am ET
PAVmed Reschedules Business Update Conference Call on February 22, 2021 to 8:30 AM EST
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company has moved the time of its business update conference call on Monday,...
Feb 17, 2021 08:31 am ET
Thinking about buying stock in PAVmed, Kintara Therapeutics, Seelos Therapeutics, Novan, or Verastem?
NEW YORK, Feb. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PAVM, KTRA, SEEL, NOVN, and VSTM.
Feb 16, 2021 09:30 am ET
First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed’s CarpX® Device
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the first U.S. patient recently underwent successful carpal tunnel release...
Feb 11, 2021 07:30 am ET
Global Cardiovascular Devices Market Now Project to Exceed $71 Billion By 2027
Palm Beach, Fl., Feb. 11, 2021 /PRNewswire/ -- Cardiovascular devices are the medical devices which are used to diagnosis and treat the heart diseases and other heart-related problems.  These devices play essential role prevention and treatment of cardiovascular diseases. The cardiovascular devices include implantable cardioverter defibrillators, implanted heart rhythm monitors, pacemakers, and various other devices. The cardiovascular devices market is currently witnessing considerable demand across the globe. Increasing awareness about the various cardiovascular diseases and increasing ger
Feb 09, 2021 09:30 am ET
PAVmed to Hold Business Update Conference Call on February 22, 2021
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conference call on Monday, February 22,...
Jan 08, 2021 10:53 am ET
PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq Rules
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct offering (the “Offering”) of...
Jan 06, 2021 09:29 am ET
PAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of 6.0 million shares of common stock at a...
Dec 22, 2020 12:04 pm ET
PAVmed Closes Additional $8.1 Million Common Stock Registered Direct Offering
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct offering (the “Offering”) of...
Dec 18, 2020 09:29 am ET
PAVmed Announces Pricing of Additional $8.1 Million Common Stock Registered Direct Offering
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of approximately 5.1 million shares of...
Dec 11, 2020 09:29 am ET
PAVmed Announces Registered Direct Offering of its Common Stock
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of 5.6 million shares of common stock in a...
Nov 17, 2020 04:00 pm ET
PAVmed Reports Third Quarter 2020 Financial Results and Provides Business Update
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (“Lucid”)...
Nov 02, 2020 09:30 am ET
PAVmed to Hold Business Update Conference Call on November 17, 2020
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conference call on Tuesday, November 17,...
Sep 08, 2020 09:30 am ET
PAVmed to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15, 2020
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will...
Aug 31, 2020 05:00 pm ET
(LD Micro) 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 27, 2020 09:30 am ET
PAVmed to Present at The LD 500 Virtual Conference
NEW YORK, NY / ACCESSWIRE / August 27, 2020 / PAVmed Inc. (NASDAQ:PAVM)(NASDAQ:PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3, 2020 at 7:20 a.m. PST / 10:20 a.m. EST. Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will be presenting a corporate overview to a live audience.
Aug 18, 2020 04:14 pm ET
PAVmed Reports Second Quarter 2020 Financial Results and Provides Business Update
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today reported financial results for the three and six months ended June 30, 2020 and provided a...
Aug 14, 2020 07:30 am ET
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of...
Aug 06, 2020 09:27 am ET
PAVmed Secures $7 Million Convertible Note Financing
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has received approximately $7 million in gross proceeds from a private placement (the...
Aug 05, 2020 09:00 am ET
LD Micro Announces Preliminary List of Presenters for the LD-500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Jul 28, 2020 09:30 am ET
PAVmed to Hold Business Update Conference Call on August 18, 2020
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conference call on Tuesday, August 18, 2020...
Jul 13, 2020 09:30 am ET
PAVmed to Present at Maxim Group’s COVID-19 Webinar on July 16, 2020
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that Shaun O’Neil, Chief Commercial Officer of the Company, will participate in a panel...
Jun 17, 2020 09:30 am ET
PAVmed to Join the Russell 2000® and Russell 3000® Indexes
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company is set to join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index as...
Jun 15, 2020 09:30 am ET
Founder and Former Chairman & CEO of Exact Sciences Stanley Lapidus Joins PAVmed Subsidiary Lucid Diagnostics as Strategic Advisor
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that medical diagnostics pioneer Stanley Lapidus, founder and former Chairman and CEO of Exact Sciences...
Jun 15, 2020 07:30 am ET
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of...
Jun 11, 2020 09:30 am ET
PAVmed Subsidiary Lucid Diagnostics Receives Preliminary Payment Determination for EsoGuard™ Esophageal DNA Test
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), received preliminary gapfill payment...
Jun 03, 2020 09:30 am ET
PAVmed Collaborates with Canon on DisappEAR™ Pediatric Ear Tubes
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company and global manufacturer Canon Inc.’s United States manufacturing and technology center, Canon...
May 21, 2020 04:00 pm ET
PAVmed Reports Preliminary First Quarter 2020 Financial Results and Provides Business Update
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported preliminary financial results for the three months ended March 31, 2020 and provided a business update....
May 11, 2020 09:30 am ET
PAVmed to Hold Business Update Conference Call on May 21, 2020
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will host a business update conference call on Thursday, May 21, 2020 at 4:30 p.m. Eastern...
Apr 21, 2020 09:30 am ET
PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel Device
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for its CarpX™...
Apr 09, 2020 04:44 pm ET
PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported preliminary financial results for the three and 12 months ended December 31, 2019 and provided a business...
Apr 02, 2020 09:30 am ET
PAVmed Subsidiary Lucid Diagnostics’ EsoCheck Esophageal Cell Collection Device Receives Prestigious Edison Best New Product Award
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the EsoCheck™ Esophageal Cell Collection Device with Collect+Protect™ Technology, developed and...
Mar 31, 2020 09:30 am ET
PAVmed Receives $6.3 Million in Gross Proceeds from Completion of November 2019 Financing
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received $6.3 million in new gross proceeds from the prepayment of promissory notes issued in...
Mar 24, 2020 09:30 am ET
PAVmed to Hold Business Update Conference Call on April 9, 2020
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report fourth quarter 2019 financial results after the market close on Thursday,...
Mar 09, 2020 09:30 am ET
PAVmed Announces FDA 510(k) Re-submission for its CarpX™ Minimally Invasive Carpal Tunnel Device
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the U.S. Food and Drug Administration (FDA) has acknowledged receipt of a 510(k) premarket notification...
Mar 02, 2020 09:30 am ET
PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has entered into a clinical trial...
Feb 20, 2020 09:30 am ET
PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett’s Esophagus (BE) Progression Biomarkers Using EsoCheck™
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has entered into a sponsored research...
Feb 18, 2020 09:30 am ET
PAVmed Adds EsoCure™ Esophageal Ablation Device with Patented Caldus™ Technology to Commercial Product Pipeline
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has added the EsoCure™ Esophageal Ablation Device with Caldus™ Technology to its commercial product...
Feb 11, 2020 09:30 am ET
U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company’s majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has received Breakthrough...
Jan 13, 2020 09:30 am ET
PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) of compliance with Nasdaq...
Dec 19, 2019 09:30 am ET
PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”) has launched its EsoGuard™ Esophageal...
Dec 13, 2019 09:30 am ET
PAVmed Provides Update on CarpX™ Clinical Safety Study
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on its CarpX™ first-in-human (FIH) 510(k) clinical safety study. This week, senior PAVmed...
Nov 21, 2019 04:00 pm ET
PAVmed Reports Third Quarter 2019 Financial Results and Provides Business Update
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and nine months ended September 30, 2019 and provided a business update....
Nov 14, 2019 09:30 am ET
PAVmed Partners with Laser Technology Pioneer Dr. Jacob Wong to Develop and Commercialize Non-Invasive Laser-based Diagnostic Products
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company and its newly formed subsidiary, Solys Diagnostics Inc. (“Solys”), have entered into definitive...
Nov 07, 2019 09:30 am ET
PAVmed’s PortIO™ Intraosseous Infusion System Achieves Multiple Milestones
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its groundbreaking PortIO™ Intraosseous Infusion System has achieved multiple important development,...
Nov 06, 2019 09:30 am ET
PAVmed to Hold Business Update Conference Call on November 21, 2019
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will file its SEC 10-Q quarterly report on or before the November 14, 2019 deadline,...
Nov 05, 2019 07:00 am ET
PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has entered into a financing agreement (the “Financing”) with an existing and a new institutional...
Sep 05, 2019 09:30 am ET
PAVmed Reports Second Quarter 2019 Financial Results and Provides Business Update
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and six months ended June 30, 2019 and provided a business update. “The...
Aug 21, 2019 09:30 am ET
USPTO Grants PAVmed Patent Covering its CarpX™ Device
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 10,335,189 which covers the...
Aug 15, 2019 09:30 am ET
PAVmed Successfully Completes Clinical Safety Study Procedures for CarpX™ 510(k) Re-submission
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that all 20 patients of its first-in-human (FIH) 510(k) clinical safety study underwent successful CarpX...
Aug 07, 2019 09:30 am ET
PAVmed to Hold Business Update Conference Call on September 5, 2019
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will file its SEC 10-Q quarterly report on or before the August 14, 2019 deadline, report...
Jun 26, 2019 09:30 am ET
PAVmed to Join Russell Microcap® Index
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company is set to join the Russell Microcap® Index at the conclusion of the 2019 Russell indexes annual...
Jun 24, 2019 10:46 am ET
PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has received 510(k) marketing...
May 21, 2019 09:30 am ET
PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three months ended March 31, 2019 and provided a business update. MANAGEMENT...
May 20, 2019 09:30 am ET
PAVmed Announces First Human CarpX™ Procedures
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the first group of nine patients with carpal tunnel syndrome underwent successful CarpX procedures as...
May 06, 2019 09:30 am ET
PAVmed to Hold Business Update Conference Call on May 21, 2019
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report first quarter 2019 financial results on or before May 21, 2019 and host a...
Apr 24, 2019 09:30 am ET
PAVmed Reports Excellent DisappEAR™ Animal Study Results
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its DisappEAR™ resorbable pediatric ear tube achieved a major developmental milestone with the...
Apr 18, 2019 08:20 am ET
Consolidated Research: 2019 Summary Expectations for Intec Pharma, Cerecor, Chiasma, Exela Technologies, PAVmed, and CUI Global — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Intec Pharma Ltd. (NASDAQ:NTEC), Cerecor Inc. (NASDAQ:CERC), Chiasma,...
Apr 12, 2019 09:35 am ET
PAVmed Announces Registered Direct Offering of its Common Stock
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has entered into agreements for the sale of 1,655,000 shares of common stock in a registered direct...
Apr 04, 2019 09:30 am ET
PAVmed Reports Fourth Quarter 2018 Financial Results and Provides Business Update
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and 12 months ended December 31, 2018 and provided a business update....
Mar 21, 2019 07:30 am ET
PAVmed to Hold Business Update Conference Call on April 4, 2019
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report fourth quarter 2018 financial results on or before April 4, 2019 and host a...
Mar 20, 2019 07:30 am ET
PAVmed Announces NextFlo™ Breakthrough
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its NextFlo™ Infusion System (“NextFlo”) achieved a key milestone in its quest to eliminate the need...
Mar 13, 2019 08:04 am ET
PAVmed Announces PortIO™ Breakthrough
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its PortIO™ Intraosseous Infusion System, which consists of an implantable intraosseous vascular...
Feb 28, 2019 12:49 pm ET
PAVmed Subsidiary Lucid Diagnostics Launches World-Class Medical Advisory Board and Appoints Chief Medical Officer
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its subsidiary, Lucid Diagnostics Inc. (“Lucid”), has launched a world-class medical advisory board...
Feb 26, 2019 07:30 am ET
PAVmed Provides Business Update
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on its business. “I am pleased to report that PAVmed’s 2019 is off to an excellent start with...
Jan 10, 2019 07:30 am ET
PAVmed Provides Business Update
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on its business. “The PAVmed team and its partners had a very active and productive finish to...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.